Nitisinon Dipharma (Nitisinone)

Nitisinone, the active ingredient in Nitisinon Dipharma, is a tyrosine metabolism inhibitor presented as an oral dosage form for oral use. It treats hereditary tyrosinemia type I in patients with the condition.

GNH USA supplies Nitisinon Dipharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Nitisinone acts on the tyrosine degradation pathway to manage hereditary tyrosinemia type I.

Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites and improves liver function. Hereditary tyrosinemia type I (pre‑transplant): helps stabilize metabolic status to allow safe liver transplantation. Hereditary tyrosinemia type I (post‑transplant): maintains metabolic control and reduces risk of disease recurrence.

Nitisinone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may improve with food. - Abdominal pain: intermittent discomfort. - Fatigue: generalized tiredness. - Skin rash: erythematous or pruritic lesions. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Hepatic failure: severe liver dysfunction requiring monitoring. - Severe anemia: marked reduction in hemoglobin. - Neutropenia: low neutrophil count increasing infection risk. - Peripheral neuropathy: tingling or numbness in extremities. - Hypersensitivity reactions: including angioedema or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures.

Monitor liver function: obtain baseline and periodic transaminase levels. Assess renal function: evaluate creatinine clearance and adjust if necessary. Avoid use in patients with known hypersensitivity to nitisinone or excipients. Use caution in pregnancy: potential risks are not well defined. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Nitisinone can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Warfarin: may potentiate anticoagulant effect and increase bleeding risk. - Strong CYP450 inducers (e.g., rifampicin, carbamazepine): can lower nitisinone plasma concentrations. - Other HPPD inhibitors: additive toxicity to the tyrosine pathway.

Moderate Interactions (Monitor Closely): - Acetaminophen: monitor liver enzymes for potential hepatotoxicity. - NSAIDs: watch renal function, especially in patients with pre‑existing kidney disease. - Anticonvulsants (e.g., phenytoin): may alter nitisinone metabolism; check therapeutic levels.